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To evaluate the eﬀect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as
preventive versus as curative treatment. The study comprised 52 male Wistar rats, divided in 5 groups, during a 20-week protocol:
control: vehicle, carcinogen: 0.05% of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), CEL: 10mg/kg/day of the selective COX-
2 inhibitor Celebrex, preventive CEL (CEL+BBN-P), and curative CEL (BBN+CEL-C) groups. Although tumor growth was
markedly inhibited by the preventive application of CEL, it was even aggravated by the curative treatment. The incidence of gross
bladder carcinoma was: control 0/8(0%), BBN 13/20(65%), CEL 0/8(0%), CEL+BBN-P 1/8(12.5%), and BBN+CEL-C 6/8(75%).
The number and volume of carcinomas were signiﬁcantly lower in the CEL+BBN-P versus BBN, accompanied by an ample
reduction in hyperplasia, dysplasia, and papillary tumors as well as COX-2 immunostaining. In spite of the reduction of tumor
volumes in the curative BBN+CEL-C group, tumor malignancy was augmented. An anti-inﬂammatory and antioxidant proﬁle
was encountered only in the group under preventive treatment. In conclusion, preventive, but not curative, celecoxib treatment
promoted a striking inhibitory eﬀect on bladder cancer development, reinforcing the potential role of chemopreventive strategies
based on cyclooxygenase 2 inhibition.
1.Introduction
Bladder cancer is a prevalent tumor, accounting for 5%–
10% of all malignancies in Western countries [1, 2]. It has
a high recurrence and progression rate and the prognosis,
except for superﬁcial forms, is poor [3]. Furthermore,
it has high mortality rates and socioeconomic costs [4,
5]. The conventional surgical techniques and therapeutic
options might cause discomfort to patients, especially in
invasive and aggressive forms of cancer [6, 7]. Therefore,
the improvement of bladder cancer management and treat-
ment could rely on better preventive strategies. The identi-
ﬁcation of promising drugs remains dependent on a better
elucidationofthemolecular/cellularmechanisms underlying
cancer appearance and progression [8, 9]. Apart from the
genetic features and markers already characterized [10, 11],
the cellular and molecular mechanisms for development
and/or progression might involve inﬂammatory, prolifera-
tive, and oxidative stress phenomena that should be better
elucidated.2 Mediators of Inﬂammation
Inﬂammation through the cyclooxygenase (COX) path-
way has been involved in cancer development [12]. While
COX-1 is constitutively expressed in a huge range of
tissues, playing a role in prostaglandins production and
maintenance of homeostasis, COX-2 expression is induced
by cytokines and growth/tumor factors, usually as a reaction
to an inﬂammatory process [13]. Previous studies have been
suggestinga keyrole of COX-2in carcinogenesis [12,14]an d
its modulation has been associated with reduction of tumor
incidence in experimental and clinical studies for distinct
types of carcinomas [15–17]. Since COX-2 overexpression
has been reported in bladder tumors [8, 18–21], COX-
2 inhibitors (Coxibs) might be viewed as promising for
chemoprevention of this cancer.
Bladder cancer, induced in rats with the carcinogen
N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), has been
used as a model for study pathophysiology and therapeutics
of this cancer [22], particularly due to the histological
similarities with the human transitional cell carcinoma [23,
24]. Previous studies have demonstrated a positive response
to some prevention strategies [25, 26], but the curative
eﬃcacy of new and promising pharmacological options,
such as the celecoxib, remains to be elucidated. Considering
the poor prognosis for a high percentage of the patients
diagnosed for bladder cancer, as well as the high recurrence
and progression rates, curative strategies might assume a key
relevance in the management/treatment of these carcinomas
in many patients.
This study aimed to evaluate, using a rat bladder carcin-
ogenesis model, the preventive versus curative eﬃcacy of the
COX-2 inhibitor Celecoxib (CEL) on bladder cancer.
2.MaterialandMethods
2.1. Animals and Groups. Male Wistar rats (Charles River
Lab. Inc, Barcelona, Spain), 250–285g, were maintained in
an air-conditioned room, subjected to 12-hour dark/light
cycles and given standard laboratory rat chow (IPM-R20,
Letica, Barcelona, Spain) and free access to tap water. Animal
experiments were conducted according to the European
CommunityCouncilDirectiveson Animal Careand with the
National Institutions for Science & Technology.
The animals were divided in ﬁve groups: control group
(n = 8): vehicle (orange juice); carcinogen (BBN) group
(n = 20): 0.05% of N-butyl-N-(4-hydroxybutyl) nitro-
samine (Tokyo Chemical Industry Co., Ltd, Tokyo, Japan);
celecoxib (CEL) group (n = 8): 10mg/kg/day of the
selective COX-2 inhibitor celebrex (Laborat´ orios Pﬁzer, S.a.,
Lisbon, Portugal); preventive celecoxib group (n = 8):
CEL+BBN-P; curative celecoxib group (n = 8): BBN+CEL-
C. Treatments were performed according to a two-step
protocol: a ﬁrst period of eight weeks for tumor induction
and pharmacological treatment (orange juice, BBN, CEL
control, and preventive CEL) and a second one of 12 weeks
for cancer expression/prevention. In the curative treatment,
rats were ﬁrst treated with BBN for 8 weeks and, thereafter,
withCELuntil theweek 20.BBNwas givenindrinking water
and orange juice (given to all groups) and CEL (prepared
in vehicle) were given by an esophageal cannula. All the
animals have completed the 20-week protocol. Body weight
and beverageconsumption were monitored during the entire
experiment.
2.2. Tumor Data Analysis
2.2.1. Bladder Removal. The rats were sacriﬁced by cervical
dislocation, and the lungs, stomach, liver, kidneys, and
intestines were immediately removed, weighted, and placed
in formaldehyde for further analysis. Before removal, blad-
ders were intraluminally injected with a buﬀered formalde-
hyde solution as preﬁxation for histological analyses.
2.2.2. Quantitative Analysis (Number and Volume of Tumors).
Each bladder preﬁxated in formaldehyde was carefully open,
the lumen was inspected for grossly visible lesions and the
number of tumors per rat and the volume of each tumor
were reported in order to further calculate the % of tumor
per group and the mean volume per rat and tumor.
2.2.3. Qualitative Analysis (Bladder Histology). The bladder
was immersion-ﬁxed in 4% buﬀered formaldehyde and
processed for paraﬃn sectioning. Three slices from each
bladder were embedded. Three micrometer thick sections
were stained with haematoxylin and eosin (H&E) and exam-
ined histologically by one author (M.F. Cunha) unknowing
the treatments.
2.3. Renal and Liver Data
2.3.1. Blood Collection and Preparation. At the end of
treatments the rats were injected with intraperitoneal
anesthesia with 2mg/KgBW of a 2:1 (v:v) 50mg/mL
Ketamine (Ketalar, Parke-Davis, Pﬁzer Lab., Seixal, Portugal)
solution in 2.5% chlorpromazine (Largatil, Rhˆ one-Poulenc
Rorer, Vit´ oria lab., Amadora, Portugal). Blood samples were
immediately collected by venipuncture from the jugular
vein in needles with no anticoagulant (for serum samples
collection).
2.3.2. Renal and Liver Data. Serum creatinine, urea, and
uric acid concentrations were used as renal function indexes
and serum aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels were assessed for liver evalua-
tion, through automatic validated methods and equipments
(Hitachi 717 analyser, Roche Diag. Inc., MA, USA).
2.4. COX-2 Immunostaining. Formalin-ﬁxed, paraﬃn-
embedded tissue blocks were sectioned at 5mm thickness,
and immunostaining was performed using the avidin-
biotin peroxidase method. Sections were deparaﬃnized
and blocked for endogenous peroxidase in 0.3% H2O2
in methanol for 20 minutes. Antigen enhancement was
performed by pretreating with microwave heating in a
citrate buﬀer, pH 6.00 (twice for 5 minutes each at 750W).
The slides were washed three times, 2 minutes each, and
then incubated with blocking serum for 10 minutes toMediators of Inﬂammation 3
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Figure 1: Macroscopic histomorphological evaluation of bladders. All the bladders from the control (a) and CEL (data not shown) treated
rats have revealed a pattern of normality, with absence of any type of malignity. In the BBN group (b), 65.0% of the rats had bladder
tumors, almost all easily seen by macroscopic analysis. The bladder walls were thicker, with new or enlarged small vessels, suggesting
neo-angiogenesis, and there was unequivocal formation of tumor (some bladder presented more than one tumor). In the preventive CEL
(CEL+BBN-P group) treatment (c), except in one case, all bladders shows a similar pattern to those seen for the control or CEL rats, with
macroscopically unrecognized signs of abnormality. However, in the curative CEL (BBN+CEL-C group) use (d), there was 75% of tumor
incidence, with even more malignant neoplasic lesions.
block the nonspeciﬁc binding. The excess of blocking serum
was removed, and then the sections were incubated at
4C overnight with primary polyclonal antibody against
COX-2 at proper dilution and secondary antibody was then
applied (Cayman Chemical Co., Ann Arbor, MI, USA).
Reactivity was visualized with an avidin-biotin complex
immunoperoxidase system using diaminobenzidine as the
chromogen and Mayer’s hematoxylin as the counterstain.
Sections of normal urothelium were included in all
experiments. In addition, many tumor sections contained
adjacent normal bladder mucosa, which served as internal
controls. Known strong COX-2 staining specimens served as
positive controls. All slides were reviewed independently by
2 investigators blinded to the data.
2.5. Serum Inﬂammatory Proﬁle and Redox Status. Serum
levels of interleukin 1β (IL-1β) were measured by ultrasen-
sitive Quantikine ELISA kits (R&D Systems, Minneapolis,
USA) and C-reactive protein (CRP) by using an ELISA kit
fromHelicaBiosystems, Inc.(Fullerton,CA,USA).Allassays
were performed in duplicate.
The thiobarbituric acid reactive-species (TBARs) assay
was used to assess serum products of lipid peroxida-
tion, via malondialdehyde (MDA), according to previously
described [27]. Samples were analysed spectrophotometri-
cally at 532nm using 1,1,3,3-tetramethoxypropane as exter-
nal standard. The serum concentration of lipid peroxides (in
MDA) was expressed as μmol/l. Ferric reducing antioxidant
potential (FRAP) assay was used to estimate serum total
antioxidant status (TAS) [28].
2.6. Statistical Analysis. We used the Statview 4.53 software
from Abacus Concepts Inc. (Berkeley, CA, USA). Results
are means ± standard error of means (SEM). Comparisons
between groups were performed using ANOVA and Mann-
Whitney post hoc test. Signiﬁcance was accepted at P less
than .05.
3.Results
3.1. Preventive versus Curative Eﬀect of Celecoxib on
Tumor Growth
3.1.1. Macroscopic Evaluation. All formaldehyde preﬁxated
bladders were opened and analysed macroscopically for
wall (urothelium) texture, thickness, and vascularization
(Figure 1). The number of rats with tumor, the number of
tumors per rat, and the volume of each tumor were reported4 Mediators of Inﬂammation
Table 1: The preventive versus curative eﬀect of Celecoxib on bladder cancer: quantitative evaluation of urothelium lesions.
Macroscopy Control CEL BBN CEL+BBN-P BBN+CEL-C
(quantitative) (n = 8) (n = 8) (n = 20) (n = 8) (n = 8)
Tumor number (%)
% of rats with tumor 0 0 (13 in 20) 65.0% (1 in 8) 12.5% (6 in 8) 75.0%
Nr tumors/rat with tumor 0 0 1.2 ±0.1 (16 in 13) 4.0† (4 in 1) 1.8 ±0.5 (11 in 6)
Tumor volume (mm3)
Mean/rat with tumor 0 0 138.5 ± 7.5 (in 13) 21.2† (in 1) 59.8 ±20.8( i n6 )
Mean/tumor 0 0 112.5 ± 6.4 (in 16) 5.3 ±0.4 (in 4) 35.9 ±14.8 (in 11)
†Represents only 1 rat in 8 of the group (s.e.m. in not applicable). Values are mean ± SEM, excepting for % of rats with tumor. BBN: N-butyl-N-(4-
hydroxybutyl) nitrosamine; CEL: celecoxib; C: curative; P: preventive.
Table 2 :T h ep r e v e n t i v ev e r s u sc u r a t i v ee ﬀect of Celecoxib on bladder cancer: qualitative evaluation of urothelium lesions.
Microscopy Control CEL BBN (n = 20) CEL+BBN-P (n = 8) BBN+CEL-C (n = 8)
(qualitative) (n = 8) (n = 8) Tumor group Total group Tumor group Total group Tumor group Total group
Preneoplasic lesions: %(nr/nr)
Hyperplasia 0 0 100 (13/13) 100 (20/20) 100 (1/1) 37.5 (3/8) 100 (6/6) 100 (8/8)
High-Grade Dysplasia 0 0 100 (13/13) 75 (15/20) 0 (0/1) 0 (0/8) 14 (1/6) 12.5 (1/8)
Low-Grade Dysplasia 0 0 0 (0/13) 25 (5/20) 100 (1/1) 12.5 (1/8) 83 (5/6) 62.5 (5/8)
Neoplasic lesions: %(nr/nr)
Papillary tumor 0 0 100 (13/13) 65 (13/20) 100 (1/1) 12.5 (1/8) 100 (6/6) 75 (6/8)
Inﬁltrative tumor 0 0 15 (2/13) 10 (2/20) 0 (0/1) 0 (0/8) 0 (0/6) 0 (0/8)
Carcinoma In Situ 0 0 31 (4/13) 20 (4/20) 0 (0/1) 0 (0/8) 0 (0/6) 0 (0/8)
BBN: N-butyl-N-(4-hydroxybutyl) nitrosamine; CEL: celecoxib; C: curative; P: preventive.
in order to further calculate the % of rats with tumor in each
group, the number of tumors per rat with tumor, as well as
the mean tumor volume per rat and per tumor (Table 1).
All the bladders from the control animals have revealed a
pattern of normality, with absence of any type of malignity.
The wall texture, thickness, and vascularization were normal
(Figure 1(a)). Similar proﬁle was found for the CEL group,
with limpid,translucent,and tiny bladders,withoutpresence
of any abnormal mass or vascularization (data not shown).
In the BBN group, however, 65.0% of the rats had bladder
tumors, almost all easily seen by macroscopic analysis. The
bladder walls were thicker, with new or enlarged small ves-
sels, suggesting neo-angiogenesis, and there was unequivocal
formation of tumor. Furthermore, some bladders presented
more than one tumor (Figure 1(b)). In the preventive
CEL+BBN-P group, apart from one case, all bladders show
a similar pattern to those seen for the control or CEL rats,
with macroscopically unrecognized signs of abnormality
(Figure 1(c)), which contrasts with the bladders from the
curative BBN+CEL-C group (Figure 1(d)).
3.1.2. Quantitative Evaluation. In the control group, as
expected, no rat developed bladder cancer. The same proﬁle
was found for the CEL animals. In the BBN group (n = 20
rats), the percentage of rats with bladder cancer was 65.0%
(13 in 20), with a mean of 1.2 ± 0.1t u m o r sp e rr a tw i t h
tumor. Furthermore, the mean tumor volume per rat with
tumor (in 13 rats) was 138.5±7.5mm 3 and the mean tumor
volume per tumor (in 16 tumors) was 112.5 ± 6.4mm 3
(Table 1). In the preventive CEL treatment (CEL+BBN-P
group), there was notorious bladder cancer prevention, with
a percentage of tumors in the group of 12.5% (1 in 8), which
correspondstoonlyoneratwithcancerinthegroupuniverse
of 8 animals. In agreement, the mean tumor volume per rat
with tumor was 21.2 and per tumor (in 4 tumors of only
1 rat) was 5.3 ± 0.4mm 3 (Table 1). This pattern contrasts
with the ineﬀective curative CEL treatment (BBN+CEL-C
group), which did not show relevant inhibitory eﬀect on
tumor growth, demonstrated by the even higher percentage
of rats with tumors 75% (6 in 8) and number of tumors
per rat with tumour (1.8 ± 0.5, representative of 11 tumors
in 6 bladder with tumor), versus the BBN group. However,
the decreased tumor volume should be reported: the mean
tumor volume per rat with tumor (in 6 rats) was 59.8 ±
20.8mm 3 and the mean tumor volume per tumor (in 11
tumors) was 35.9 ± 14.8mm 3 (Table 1).
3.1.3. Qualitative Evaluation. Concerning the microscopic
analysis of urothelium layer and urothelial tumors, the con-
trol and the CEL rats have shown normal patterns (Figures
2(a) and 2(b), resp.). The bladder from control animals had
no signs of preneoplasic lesions (neither hyperplasia nor
dysplasia), as well as those from the CEL rats (Table 2). In
the carcinogen (BBN) group, there was evident malignant
transformation, including hyperplasia (100%) and dysplasia
(100%), present in all the animals, including those withoutMediators of Inﬂammation 5
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(d1) (d2)
(e1) (e2)
Figure 2: Microscopic histomorphologicalevaluation of bladder urothelium. The bladder from control (a) and CEL (b) treated rats had no
signs of preneoplasic lesions (neither hyperplasia nor dysplasia) or gross tumor formation. In the carcinogen (BBN) group (c), the bladder
from all the animals presented hyperplasia and high-grade dysplasia (c1), including those without tumor formation, as well as malignant
lesions, mainly papillary tumors (c2), but also inﬁltrative and CIS. In the preventive CEL+BBN-P treatment (d), only one bladder of the 8
rats presented tumor formation with dysplasia (d1), while all the other rats have presented a normal urothelium proﬁle (d2), contrasting
with the pattern found in the curative CEL (BBN+CEL-C group) use (e), which reveals preneoplasic, including high-grade hyperplasia and
dysplasia (e1), and neoplasic lesions, even more malignant(e2) (H&E staining(x100)).
tumor formation (Table 2 and Figure 2(c1)). Furthermore,
there were also malignant lesions, papillary, inﬁltrative, and
CIS (Table 2 and Figure 2(c2)). The preventive use of CEL
(group CEL+BBN-P) has undoubtedly prevented bladder
cancer development. Therefore, as above mentioned, only
one bladder of the 8 rats from the group has shown cancer
development (12.5% of the rats from the group) (Table 1).
Apart from the rat with tumors (all papillary), whose
urothelium has demonstrated hyperplasia and dysplasia,
without inﬁltrative or CIS (Table 2 and Figure 2(d1)), all
the other rats have presented a normal urothelium proﬁle
(there was only low-grade hyperplasia in two of those 7
animals) (Table 2 and Figure 2(d2)). On the contrary, the
curative CEL treatment (BBN+CEL-C group), despite lower
tumor volume (Table 1), not only did not reverse tumor
(75%)and preneoplasiclesions (hyperplasia and metaplasia)
development (Table 2 and Figure 2(e1)) but also promoted
increased malignancy, presenting more aggressive (T1G2)
carcinomas (Table 2 and Figure 2(e2)).
The lungs, stomach, liver, kidneys, and intestines were
normal on gross inspection and on histological examination
for all the groups under study. Body weight and beverage6 Mediators of Inﬂammation
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Figure 3: Serum markers of inﬂammation: C-Reactive Protein (a) and Interleukin-1β (IL-1β)—in the ﬁve groups under study. Values are
mean±SEM. aaa-P<. 001versusthecontrolgroup; bbb-P<. 001versustheBBNgroupand c-P<. 05and ccc-P<. 001versustheCEL+BBN-P
group.
consumption were almost unchanged between the groups,
not interfering with the tumor data analysis (data not
shown).
3.2. Serum Inﬂammatory Proﬁle and Redox Status Markers.
Serum CRP levels were signiﬁcantly higher (P<. 001) in
the BBN rats, when compared with the control animals.
In all the CEL groups, however, CRP concentration was
substantially lower (P<. 001) than that of the control
and BBN rats (Figure 3(a)). Serum IL-1β contents were
unchanged between the control, CEL, and BBN groups.
While in the preventiveCEL treatment (CEL+BBN-Pgroup)
the concentration was identical to those of the BBN rats,
in the curative CEL use (BBN+BBN-C group) there was
a remarkable increment (P<. 001) in IL-1β serum levels
(Figure 3(b)).
Concerning the serum redox status markers, in the BBN
rats there was a trend to higher serum lipid peroxidation
marker (MDA) content versus the control, and a signiﬁcant
reduction (P<. 05) in the CEL rats. While the preventive
CEL treatment (CEL+BBN-P group) promoted a reduction
(P<. 01) of serum MDA, versus the BBN group, the
curative CEL use (BBN+BBN-C group) further signiﬁcantly
aggravated (P<. 001) the MDA increment (Figure 4(a)).
This group also shows a signiﬁcant augment of serum total
antioxidant status (TAS), eventually as a counteraction
against the increment of reactive species (which is suggested
by the notable MDA increase). All the other groups showedMediators of Inﬂammation 7
0
0.5
1
1.5
2
S
e
r
u
m
M
D
A
(
μ
m
o
l
/
L
)
bb
bbb
ccc
Control BBN CEL CEL +
BBN-P
CEL +
BBN-C
a
(a)
0
200
400
600
800
S
e
r
u
m
T
A
S
(
μ
m
o
l
/
L
)
bbb
ccc
Control BBN CEL CEL +
BBN-P
CEL +
BBN-C
(b)
0
1
2
3
S
e
r
u
m
M
D
A
/
T
A
S
×103
bbb
ccc
Control BBN CEL CEL +
BBN-P
CEL +
BBN-C
b a
(c)
Figure 4: Serum markers of redox status: lipid peroxidation, through MDA (a), total antioxidant status (b), and MDA/TAS (c)—in the ﬁve
groups under study. Values are mean ± SEM. a-P<. 05 versus the control group; b-P<. 05, bb-P<. 01, and bbb-P<. 001 versus the BBN
group; ccc-P<. 001 versus the CEL+BBN-P group.
an unchanged patter for serum TAS (Figure 4(b)). As a
result,theratioMDA/TASwasreducedintheCELgroupand
unchanged in the BBN rats, versus the control signiﬁcantly
diminished in the preventive CEL treatment (CEL+BBN-P
group), and notably increased in the curative CEL group
(BBN+BBN-C),versus the BBN animals (Figure 4(c)).
3.3. COX-2 Immunostaining. In the control (Figure 5(a))
and CEL groups (Figure 5(b)), COX-2 imunostaining was
only slightly evident in the external urothelium layer,
demonstrating even less presence in the suburothelial layers.
However, in the BBN group, both the areas of preneoplasic
lesions (such as hyperplasia, Figure 5(c1)) and of neoplasic
formations (such as papillary tumors, Figure 5(c2)) were
intensely stained for COX-2, demonstrating an unequivocal
overexpression. In the preventive CEL+BBN-P treatment
(d), only one bladder of the 8 rats presented tumor
formation, in which COX-2 staining was encountered, but
only in the external layer of the papillary tumor region
(Figure 5(d1)), while no signiﬁcant staining was found in
the nontumoral urothelium (Figure 5(d2)). In the curative
CEL treatment (BBN+CEL-C group), in which Celecoxib
use was performed between the weeks 12 and 20, after
which the bladders were collected, the non-neoplasic areas
showed a clear inhibition of COX-2 (Figure 5(e1)), which is
in agreement with the treatment performed. However, in the
tumor lesion, an intense COX-2 immunostaining was found
(Figure 5(e2)),demonstrating a clear overexpression, similar
to that encountered in the BBN-treated rats.
3.4. Renal and Liver Data. In the BBN group, there
was a trend to lower values of urea and higher of
uric acid, when compared with the control group, with-
out signiﬁcant changes of serum creatinine content. An
inversely proﬁle, also nonsigniﬁcant, was found for the
CEL group. In the group under preventive CEL+BBN-
P treatment, all biochemical renal parameters (creatinine:
64.53±2.65μmol/L;urea: 18.55±0.71μmol/L and uric acid:8 Mediators of Inﬂammation
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Figure 5: COX-2 immunohistochemistry (the positivity is the brown nuclear staining) in the ﬁve groups under study: control (a), CEL (b),
carcinogen (BBN) group (c1 and c2), preventive CEL+BBN-P treatment (d1 and d2), and curative CEL (BBN+CEL-C group) use (e1 and
e2) (original magniﬁcation X 400).
109.44 ± 14.87μmol/L) were signiﬁcantly (P<. 01) higher
than those in the BBN group (54.81±1.77; 13.50±0.47,and
57.10±7.14,resp.), contrasting withthe curativeBBN+CEL-
C one that showed unchanged creatinine (54.70 ± 1.58) and
urea (12.64 ± 0.41) levels and lower (P<. 05) of uric acid
(39.19 ± 5.15).
Concerning the liver data, AST (78.15 ± 6.04IU/L) and
ALT (38.15 ± 2.92IU/L) for the BBN rats were higher (P<
.05) than those in the control animals (51.57 ± 1.09 and
30.86 ± 1.75, resp.), contrasting with the proﬁle of the
CEL group, identical to that of the control. However, in
the CEL+BBN-P group, both parameters (64.57 ± 4.30 and
30.14 ± 2.58, resp.) were substantially lower (P<. 01) than
those of the BBN rats, mimicking those of the CEL rats and
closer to those of the control, again contrasting with the
BBN+CEL-C data that revealed substantial higher values of
both AST (102.11 ± 11.24; P<. 05) and ALT (54.00 ± 5.14;
P<. 001) versus the BBN rats.
4.Discussion
The present study is part of an ongoing preclinical research
concerning the eﬀects of distinct agents against urinary
bladder cancer prevention or reversion. The main purposeMediators of Inﬂammation 9
wasthe assessment ofwhetherthe COX-2inhibitorcelecoxib
is eﬀective as preventive or curative therapy for bladder
carcinogenesis in an animal model previously described in
the literature using 0.05% ofBBNas the carcinogen inductor
[22].
In recent years, there has been a great interest in the
question of whether COX-2 inhibitors could prevent/revert
carcinogenesis through COX-2 modulation, which seems to
play a key role in cancer development [12, 14]. Since COX-2
downregulation has been positively linked to chemopreven-
tion in other tissues and organs [15–17], its eﬃcacy deserves
further research on the bladder cancer. Considering that,
the second step of our work was to evaluate the potential
preventive and curative eﬀect of COX-2 inhibition on
bladder carcinoma development and progression. The main
ﬁnding was that tumor growth is undoubtedly inhibited by
CEL treatment, with an incidence of only 12.5% (1 in 8
rats), with a reduced mean tumor volume per tumor of
5.3 ± 0.4mm 3 (in 4 tumors of 1 rat), contrasting with the
data from the BBN rats: 65% and 112.5 ± 6.4mm 3 (in 16
tumors of 13 rats with tumor), respectively. Furthermore,
and even more relevant, apart from the rats with tumors (all
papillary), whose urothelium has demonstrated hyperplasia
and dysplasia of low-grade, without inﬁltrative or CIS, all
the other rats (7 in 8) have presented a normal urothelium
proﬁle (there was only low-grade hyperplasia in two of those
7 animals). These data conﬁrm that this drug is eﬀective
not only for chemoprevention of gross tumor appearance
and growth but also for prevention of preneoplasic lesions
formation. These data were reinforced by the pattern of
immunochemistry found for the group, in which staining
was encountered only in the external layer of the papillary
tumor region, while no signiﬁcant staining was found in the
nontumoral urothelium.
Our study showed a remarkable chemopreventive eﬃ-
cacy on tumor growth using a lower COX-2 inhibitor
dose (10mg/kg) than those tested in other studies (200,
500, and 1250mg/kg) [29] and that better reproduce the
doses clinically used for anti-inﬂammatory actions, thus
reinforcing the markedly promising results. Moreover, apart
from some deterioration of renal markers, which might be
due to deregulation of renal prostanoids pathway or due to
low water consumption, CEL treatment has prevented BBN-
induced liver impairment, suggesting that a low-dose cele-
coxib is not aggressive concerning the main organ functions.
Inrelationtothenatureofurotheliumlesion,thehyperplasia
and high-grade dysplasia induced by the carcinogen were
highly prevented, decreasing from an incidence of 100% to
12.5%, together with a total prevention of papillary tumors
and carcinomas.
Apart from the chemopreventive eﬀect of selective COX-
2 inhibition on cancer development, we were interested in
assess the putative regressive action of this drug. In clinical
practice, if a similar beneﬁt was conﬁrmed, this curative
treatment could be useful for situations of bladder cancer
irresponsive for surgical and pharmacological treatments,
which is a common situation, as demonstrated by the high
recurrence and progression rate and the poor prognosis,
particularly for initial superﬁcial forms, namely, when lately
diagnosed [3]. However, surprisingly, when used as curative
treatment, the selective COX-2 inhibition was not only
unable to inhibit tumor growth and development (75%
incidence versus 65% in the carcinogen group) but also
showed a promotion of tumor malignancy, demonstrated
b yt h ep r e s e n c eo fm o r ea g g r e s s i v et u m o rt y p e s( s u c ha s
the T1G2). Furthermore, this use of Celecoxib was more
deleterious to the liver, as shown by the increased serum
markers AST and ALT, contrasting with the preventive CEL
treatment.
Human and animal, in vitro and in vivo, studies have
proposed distinct cellular/molecular mechanisms to explain
the chemopreventive eﬀects of this group of compounds,
particularly in prostate cancer, which includes the expected
reduction of inﬂammation as a result of COX-2 inhibition,
as well as other dependent or independent pathways, such
as apoptosis induction, inhibition of cell growth, angio-
genesis suppression, induction of cell cycle arrest, inhibi-
tion of peroxisome proliferator-activated receptors (PPARs)
expression, or through other components, namely, of the
immune system [30–35]. Not excluding other eventually
relevant contributions, according to our data preventive
Celecoxib use is able to promote cancer chemoprevention
by mechanisms related with its expected anti-inﬂammatory
action, but also with antioxidant properties. Therefore,
serum CRP levels were highly reduced when compared
with the carcinogen (BBN) group, which was accompanied
by a more beneﬁcial redox status proﬁle, given by the
lower lipid peroxidation, most likely indicative of reduced
reactive oxygen species (ROS) formation. Thus, considering
that inﬂammation and oxidative stress are key fuels for
cancer development [36], the inhibition of those pathways
in very early stages of the carcinogenesis process seems
to be crucial for the prevention of tumor growth. This
idea is reinforced by the results obtained for the curative
celecoxib application, which was unable to reverse cancer
progression, even demonstrating a malignant induction.
The notorious augment of serum IL-1β in the group with
higher tumor incidence (curative CEL group) suggests a
special role of this cytokine in carcinogenesis and a potential
therapeutic target, as was suggested by other studies [37,
38]. This was accompanied by a huge increment in serum
IL-1β, demonstrating that further inﬂammatory pathways
are activated when the celecoxib is used after the tumor
induction.Moreover,inspiteoflipidperoxidationreduction,
the late CEL treatment was responsible for an undoubted
aggravation of oxidative stress, most certainly involved in
tumor progression. Our data are in agreement with the
chemopreventive activity of celecoxib against colon carcino-
genesis when the COX-2 inhibitor was administered during
the initiation stage of carcinogenesis [39]. In our study, the
curative CEL (BBN+CEL-C) group, despite a lower COX-
2 staining in non-neoplasic areas, which is in agreement
with the treatment performed (Celecoxib was given between
the end of BBN treatment, week 12, and the ﬁnal time for
bladder collection: week 20), severe COX-2 immunostaining
in the tumor lesion was encountered, demonstrating a clear
overexpression, similar to that encountered in the BBN-
treated rats.10 Mediators of Inﬂammation
The multistep nature of cancer development might
provide opportunities for intervention with agents targeted
atspeciﬁc mechanisms involvedin theinitiation, promotion,
and progression stages of cancers. Our data reinforce the
pivotalroleofinﬂammation in tumordevelopmentaswell as
the relevance of chemopreventive strategies based on earlier
COX-2 inhibition, which might be particularly relevant
for high-risk individuals as well as for patients treated
for a previous episode of bladder cancer and under high
possibility ofrecurrence. However, attentionshould be taken
when using those drugs in patients with sustained bladder
cancer, since, according to our data, cancer growth could
not be reversed and, even more preoccupant, might be yet
aggravated.
5.Conclusions
Inﬂammation, with COX-2 overexpression and/or hyper-
activity, is a major contributor to bladder tumor develop-
ment/progression. Inhibition of COX-2 by celecoxib proved
tobeapromisingpharmacologicalmodulationaschemopre-
vention of urinary bladder carcinogenesis if used earlier in
tumor growth, as preventive, but not if used as a curative or
regressive therapy. Our ﬁndings might be viewed as an open
promising opportunityfor improvement ofpharmacological
bladder cancer management based on preventive strategies
of COX-2 inhibition but should also be viewed as an alert
concerning its potential deleterious application in patients
with consistent bladder cancer stages.
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